AllQuantitative Report
logoArgusJanuary 13, 2021

EXEL: Rating decreased to a HOLD

Symbols
EXEL
Sector(s)
Healthcare
Rating
Premium
Current Price
$22.01
Price Target
$NaN
Earnings Estimate
Premium
Summary

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer.

Premium
Subscribe to Yahoo Finance Premium for full access
Read the latest independent research including analyst forecasts, ratings on the US economy, and more. Get individual company and overall sector level recommendations.
Try Premium FREE